|
Characteristic
|
Micafungin
|
Liposomal amphotericin B
|
Total
|
|---|
| |
Non-ICU (n = 127)
|
ICU (n = 120)
|
Non-ICU (n = 136)
|
ICU (n = 110)
|
Non-ICU (n = 263)
|
ICU (n = 230)
|
|---|
|
Age (years)
| | | | | | |
|
Mean ± standard deviation
|
53.1 ± 16.90
|
52.4 ± 19.40
|
53.7 ± 18.74
|
53.4 ± 17.76
|
53.4 ± 17.85
|
52.9 ± 18.60
|
|
Median
|
54.0
|
54.5
|
55.5
|
56.0
|
55.0
|
56.0
|
|
Range
|
18.0 to 87.0
|
18.0 to 89.0
|
16.0 to 89.0
|
17.0 to 97.0
|
16.0 to 89.0
|
17.0 to 97.0
|
|
Male, n (%)
|
79 (62.2)
|
76 (63.3)
|
79 (58.1)
|
68 (61.8)
|
158 (60.1)
|
144 (62.6)
|
|
Female, n (%)
|
48 (37.8)
|
44 (36.7)
|
57 (41.9)
|
42 (38.2)
|
105 (39.9)
|
86 (37.4)
|
|
Race, n (%)
| | | | | | |
|
Black
|
11 (8.7)
|
2 (1.7)
|
7 (5.1)
|
3 (2.7)
|
18 (6.8)
|
5 (2.2)
|
|
Caucasian
|
84 (66.1)
|
65 (54.2)
|
97 (71.3)
|
56 (50.9)
|
181 (68.8)
|
121 (52.6)
|
|
Other
|
32 (25.20)
|
53 (44.17)
|
32 (23.5)
|
51 (46.4)
|
64 (24.3)
|
104 (45.2)
|
|
Region, n (%)
| | | | | | |
|
Brazil
|
37 (29.1)
|
18 (15.0)
|
42 (30.9)
|
15 (13.6)
|
79 (30.0)
|
33 (14.3)
|
|
Europe
|
37 (29.1)
|
46 (38.3)
|
43 (31.6)
|
34 (30.9)
|
80 (30.4)
|
80 (34.8)
|
|
India
|
12 (9.4)
|
44 (36.7)
|
20 (14.7)
|
39 (35.5)
|
32 (12.2)
|
83 (36.1)
|
|
North America
|
11 (8.7)
|
6 (5.0)
|
12 (8.8)
|
7 (6.4)
|
23 (8.7)
|
13 (5.7)
|
|
Other
|
30 (23.6)
|
6 (5.0)
|
19 (14.0)
|
15 (13.6)
|
49 (18.6)
|
21 (9.1)
|
|
APACHE II score
| | | | | | |
|
Mean ± standard deviation
|
13.4 ± 6.32
|
18.4 ± 9.39
|
14.1 ± 6.60
|
17.8 ± 9.35
|
13.8 ± 6.46
|
18.1 ± 9.35
|
|
Median
|
13.0
|
19.0
|
14.0
|
17.0
|
14.0
|
17.5
|
|
Range
|
0 to 30.0
|
0 to 44.0
|
0 to 37.0
|
0 to 47.0
|
0 to 37.0
|
0 to 47.0
|
|
Relevant risk factors
| | | | | | |
|
Catheter present
|
95 (75.4)
|
116 (96.7)
|
93 (68.4)
|
105 (95.5)
|
188 (71.8)
|
221 (96.1)
|
|
Bone marrow transplant
|
4 (3.1)
|
2 (1.7)
|
2 (1.5)
|
1 (0.9)
|
6 (2.3)
|
3 (1.3)
|
|
Neutropenia
|
26 (20.5)
|
6 (5.0)
|
21 (15.4)
|
4 (3.6)
|
47 (17.9)
|
10 (4.3)
|
|
Persistent neutropenia during therapy
|
11 (8.8)
|
3 (2.5)
|
7 (5.3)
|
2 (1.9)
|
18 (7.0)
|
5 (2.2)
|
|
Acute leukemia
|
20 (15.7)
|
1 (0.8)
|
13 (9.6)
|
3 (2.7)
|
33 (12.5)
|
4 (1.7)
|
|
Hematological disorder
|
37 (29.1)
|
7 (5.8)
|
24 (17.6)
|
8 (7.3)
|
61 (23.2)
|
15 (6.5)
|
|
Liver disorder/failure
|
1 (0.8)
|
0 (0.0)
|
2 (1.5)
|
0 (0.0)
|
3 (1.1)
|
0 (0.0)
|
|
Pancreatitis
|
5 (3.9)
|
4 (3.3)
|
3 (2.2)
|
6 (5.5)
|
8 (3.0)
|
10 (4.3)
|
|
Renal disorder/failure
|
0 (0.0)
|
2 (1.7)
|
1 (0.7)
|
0 (0.0)
|
1 (0.4)
|
2 (0.9)
|
|
Solid organ tumor
|
23 (18.1)
|
12 (10.0)
|
27 (19.9)
|
23 (20.9)
|
50 (19.0)
|
35 (15.2)
|
|
Solid organ transplant
|
4 (3.1)
|
9 (7.5)
|
5 (3.7)
|
4 (3.6)
|
9 (3.4)
|
13 (5.7)
|
|
Antibiotic use
|
23 (18.1)
|
29 (24.2)
|
28 (20.6)
|
35 (31.8)
|
51 (19.4)
|
64 (27.8)
|
|
Corticosteroid therapy
|
14 (11.0)
|
22 (18.3)
|
20 (14.7)
|
17 (15.5)
|
34 (12.9)
|
39 (17.0)
|
|
Other immunosuppression
|
9 (7.1)
|
11 (9.2)
|
8 (5.9)
|
7 (6.4)
|
17 (6.5)
|
18 (7.8)
|
|
Intravenous line/device
|
40 (31.5)
|
26 (21.7)
|
35 (25.7)
|
20 (18.2)
|
75 (28.5)
|
46 (20.0)
|
|
Length of hospital stay
| | | | | | |
|
Mean ± standard deviation
|
21.6 ± 17.77
|
20.0 ± 20.36
|
23.2 ± 20.35
|
27.6 ± 47.59
|
22.5 ± 19.13
|
23.6 ± 36.16
|
|
Median
|
18.0
|
14.0
|
19.5
|
15.0
|
19.0
|
14.5
|
|
Range
|
2 to 82.0
|
1 to 126.0
|
1 to 97.0
|
1 to 388.0
|
1 to 97.0
|
1 to 388.0
|
- APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit.
